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Foreword
The International Undergraduate Journal of Health Science (IUJHS) which is in its second year and
is presenting its third edition continues to serve as a platform for undergraduate degree students to
have their research, peer-reviewed, edited, and published. Getting published as an
undergraduate student is a rare and perhaps intimidating prospect. Our aim for IUJHS is to
continue to make publication more accessible to undergraduate students across all disciplines of
health science. We hope that its content will further undergraduate health science education in
addition to providing the usual benefits of peer-reviewed research reporting in any scientific journal.

IUJHS is a twice-yearly, student-run, and peer-reviewed journal. Consistent with the studentcentred objective of this journal, the editorial board comprises of Chief Editor Ruth
Delahunty, Assistant Editor Sarah Randles, and a panel of student reviewers (see full list of
editorial board members), all of whom are undergraduate students. The current editorial board
looks forward to the prospects of the journal and the opportunities it will present to undergraduate
students studying health science in Ireland and further afield. Indeed, we have our first
international paper reviewed and accepted for publication in issue four due out in December 2022.

This issue has seen the impact of the pandemic with submissions to the journal at lower
levels than for the previous two issues, we believe that this reflects the lack of practical
research projects conducted during the COVID-19 pandemic. We have dedicated this issue as a
special on the COVID-19 pandemic as it was timely, and we received several excellent COVID-19
related papers. Therefore, this special issue contains a three review papers including Ada Fleming’s
overview of the novel condition Vaccine-Induced Thrombotic Thrombocytopenia (VITT) and its
emergence following the administration of adenoviral vector-based vaccines against COVID-19.
Interestingly the prognostic capability of haematological parameters in SARS Co-V2 infection is
detailed by Kevin D’Arcy. The third and final review, by Kiera O’Leary, investigates the novel
therapeutic Emicizumab-kxwh and its role in Haemophilia A therapy. These reviews make for some
very topical and relevant reading.
The editorial board would like to acknowledge our adjunct editors and IUJHS founders
Dr Lesley Cotter and Dr Brigid Lucey from the Department of Biological Sciences MTU, and Ms.
Sinead Hanrahan and Ms. Therese Ahern from the MTU library. This team has spent many hours of
their lives working towards the IUJHS which has now been launched following receipt of
funding from the National Forum for the Enhancement of Teaching and Learning. The editorial
board is also indebted to the IUJHS reviewer panel. We send our deepest thanks to our expert and
student reviewers, who so willingly gave their time and expertise to see undergraduate work
published. Their feedback was always constructive and in keeping with the ethos of the
journal, fostering a positive learning environment. This publication would not have been possible
without many individuals, but especially
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our undergraduate peers. We thank them for their submissions to the journal and their engagement with
the review process – long may this continue for our future issues.
Ruth Delahunty & Sarah Randles
Editors
June 2022
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A Review of the Pathogenesis, Clinical Features and Diagnostic Indicators
of the Novel Condition Vaccine-Induced Thrombotic Thrombocytopenia
Ada Fleming1, 2
1

2

Department of Haematology, University Hospital Kerry, Tralee, Co Kerry, Ireland

Department of Biological Sciences, Munster Technological University, Bishopstown, Cork,
Ireland

ABSTRACT
The introduction of vaccination against SARS-CoV-2 infection was a welcome and significant
event in the COVID-19 pandemic. While vaccine administration was for the most part
successful, it did come with the emergence of a novel condition, Vaccine-Induced Thrombotic
Thrombocytopenia (VITT). This condition presents after the administration of adenoviral
vector-based vaccines against COVID-19, causing thrombocytopenia and thrombosis in
affected individuals. There have been ten suspected cases of VITT in Ireland reported up to
March 2022. While its mechanism is not fully understood, the condition is characterised by the
presence of Platelet Factor 4 (PF4) antibodies. There are several laboratory indicators which
may suggest that a patient has developed VITT, but confirmatory diagnosis requires anti-PF4
ELISA and PF4 Activation Assays. Thrombocytopenia often precedes thrombosis in VITT, so
early treatment can aid in preventing the more serious implications of the condition from
developing. Early recognition and clear guidelines for diagnosis are imperative in the treatment
of VITT.
INTRODUCTION
Vaccine-Induced Thrombotic Thrombocytopenia (VITT) is a novel condition which has been
recently identified following the administration of vaccines against the pandemic disease
COVID-19. In Europe, four COVID-19 vaccines have been approved for use (EMA, 2021).
The mechanism by which these vaccines induce immunity has been well documented. Two
mRNA vaccines are in use, the Pfizer/BioNTech and Moderna vaccines. These vaccines work
through the administration of mRNA which encodes the production of an antigen. The vaccine
mRNA is taken up by cells, which are then prompted to produce the antigen, which in this case
is the spike glycoprotein of SARS-CoV-2. The immune system will then launch an immune
response against the foreign antigen which has been produced, creating antibodies which attack
the spike glycoprotein. This means that on re-infection by SARS-CoV-2, the immune system
will quickly recognise and mount an immune response against the spike glycoprotein (Chung,
Thone and Kwon, 2021). The spike glycoprotein plays an important role in the entry of
SARSCoV-2 into cells, so antibodies against this antigen will block or slow the entry of the
virus into the cells (Ortiz-Prado et al., 2020).
The other two vaccines approved for use are the AstraZeneca and Janssen vaccines, which are
both adenoviral vector-based. Viral vector vaccines work by replacing a gene responsible for
replication with a gene which encodes the required antigen in the viral vector. When
administered, this will cause cells to produce the antigen of interest, in this case the spike
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glycoprotein of SARS-CoV-2, while also preventing the virus itself from replicating
(McGonagle et al., 2021). After the production of the spike glycoprotein, the adenoviral vector
vaccines work in the same way as the mRNA-based vaccines to promote the immune system
to mount a response against the spike glycoprotein. Development of VITT follows the
administration of adenoviral-vector vaccines against SARS-CoV-2, although very rare cases of
thrombosis following mRNA vaccine administration have also been reported (Elalamy et al.,
2021).
VITT has been reported among recipients of the Oxford AstraZeneca ChAdOx1 nCov19 (now
Vaxzevria) and Janssen Ad26.COV2.S vaccines (Greinacher, Thiele et al., 2021). VITT is
uncommon and affects a low number of vaccine recipients. One of the highest incidence rates
was reported in Norway, where VITT developed in 1:22,000 individuals who received an
adenoviral vector vaccination. If left untreated the condition can have serious implications and
has in some cases caused fatality (Favaloro, 2021). For such reasons, early detection and rapid
treatment is of vital importance.
Symptoms of VITT have been seen to develop 4-42 days post vaccination and can include
headache, abdominal or back pain, focal changes, petechiae, easy bruising or bleeding, nausea
or vomiting and shortness of breath (Kotal et al., 2021). Laboratory indicators suggestive of
VITT include a low platelet count, prolonged prothrombin time (PT) and activated partial
thromboplastin time (APTT), and elevated d-dimer levels (Favaloro, 2021). If such markers are
present in a patient suspected of having VITT, further testing is warranted to confirm the
diagnosis.
VITT is characterised by the presence of Platelet Factor 4 (PF4) antibodies in individuals who
have recently received a vaccine. The presentation and mechanism of VITT is thought to be
closely like that of heparin-induced thrombotic thrombocytopenia (HIT), another condition
which is characterised by the presence of anti-PF4 antibodies (Klok et al., 2021). PF4 Anti IgG
ELISA testing and Platelet Factor 4 Induced Platelet Activation Assays (PIPA) can be used to
confirm the presence of PF4 antibodies, which will confirm the diagnosis of VITT (Lavin et
al., 2021). Since this is a newly emerging condition, little is known about what proportion of
vaccine recipients develop VITT or how the vaccine triggers the thrombotic thrombocytopenic
response seen in VITT. This review assimilates and analyses what has been reported about
VITT and discusses laboratory investigation of the condition and current treatment so far.
REPORTED INCIDENCE OF VITT
Variation in the incidence of VITT has been reported between different countries and different
age groups. In the UK, the incidence is reported as being 1:100,000 for patients over the age of
50, and 1:50,000 for patients under the age of 50 (Pavord et al., 2021). Norway has reported a
much higher incidence rate, with 1:22,000 of all individuals vaccinated developing VITT
(Wiedmann et al., 2021). It has been suggested that VITT is less prevalent in Asian populations,
as is the case with HIT. In South Korea after the administration of 7.9 million doses of
adenoviral vector-based vaccines there had only been ten cases of VITT, giving an incidence
of 1:790,000, much lower than rates reported in Europe (Kim et al., 2021). Although literature
on the incidence of VITT in Ireland has so far been minimal, it has been reported that there
have been ten suspected cases of VITT in the country to date (March 2022) with no associated
deaths. Nine of the cases occurred following vaccination with the AstraZeneca vaccine, and
one case following the Janssen vaccine (Swan et al., 2021).
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The first publications of VITT reported fatality rates was of 55-60% (Klok et al., 2021). A more
recent publication in the UK reported a fatality rate of 23%, which is still very significant
(Pavord et al., 2021). This difference in reported rates may be due to the underreporting of
cases when the condition was first described. Most cases where VITT has resulted in fatality
have been cases where extensive thrombosis has been present (Swan et al., 2021). The highest
mortality rate is associated with cases where the platelet count is below 30x109/L and
intracranial haemorrhage is reported (Pavord et al., 2021).
It has been shown that 54% of individuals affected by VITT are female (Pavord et al., 2021).
There appears to be a higher risk for younger age groups, with 85% of VITT patients being
under 60 years of age (Klok et al., 2021). Following the emergence of VITT, many countries
including Ireland, the UK, Germany, and Austria stopped the administration of the AstraZeneca
vaccine to younger age groups (Elalamy et al., 2021). The majority of VITT cases occur after
the first dose of a two-dose vaccine, and it has been recommended that any patients who
develop VITT after their first dose should receive an mRNA vaccine for their second dose
(Klok et al., 2021).
CLINICAL PRESENTATION AND GUIDELINES FOR DIAGNOSIS OF VITT
A wide range of symptoms have been reported to be associated with VITT, with the most
common including headache, nausea, visual disturbances, easy bruising, petechiae and acute
pain (Elalamy et al., 2021). On laboratory investigation, thrombocytopenia and elevated
Ddimer levels are common. Coagulation tests such as the prothrombin time (PT) and activated
partial thromboplastin time (aPTT) may be prolonged, and hypofibrinogenemia has also been
noted in numerous cases (Lavin et al., 2021). VITT is associated with thrombosis at unusual
sites, such as cerebral venous sinus thrombosis (CVST), splenic venous thrombosis (SVT) and
ophthalmic vein thrombosis (McDonnell et al., 2021), as well as more common presentations
of thrombosis such as deep-vein thrombosis (DVT) and pulmonary embolism (PE). Venous
thrombosis is also commonly present at multiple sites in VITT patients (Kotal et al., 2021).
Different publications have reported different time ranges for when the symptoms of VITT can
appear, with the widest range being 4 – 42 days post vaccination. VITT is an immune response
so any adverse reactions to a vaccination seen before 4 - 5 days post vaccination are not because
of VITT (Kotal et al., 2021).
When VITT was first recognised, the varied clinical presentation possible in VITT was not
fully appreciated. It was thought that thrombosis, thrombocytopenia, and elevated D-dimer
levels were present in all cases, and if a patient presented lacking one of these criteria VITT
was not suspected (Klok et al., 2021). One report detailed a case where a patient presented to
a hospital with headache, visual disturbance, nausea, thrombocytopenia, and elevated D-dimer
levels. Investigation found that there were no signs of thrombosis, so VITT was not suspected,
and the patient was discharged. The patient subsequently re-presented three days later with
worsening symptoms and the diagnosis of VITT was confirmed (Lavin et al., 2021). This delay
in the recognition of VITT can have a significant effect on patient outcome, so it is important
to highlight that not all cases will present with all classical signs of VITT.
One factor which may influence why there appears to be a delay between when a patient with
VITT first presents and when the diagnosis of VITT is confirmed is the discrepancy between
diagnostic guidelines which have been published since the condition emerged. One report used
four different sets of guidelines, published by the Society for Thrombosis and Haemostasias
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Research in Germany (GTH), UK Expert Haematology Panel (UK EHP), Thrombosis Canada
and International Society on Thrombosis and Haemostasis (ISTH), to evaluate case studies of
confirmed VITT cases (Lavin et al., 2021). The findings were that there was inconsistency in
what were considered diagnostic indicators between the different sets of guidelines. This
ambiguity in the recommendations for the diagnosis of VITT is a plausible reason as to why
there may have been a delay in recognising the signs of VITT when a patient first presented.
Since the identification of VITT some organisations including the UK EHP have updated their
guidelines for diagnosis (Pavord et al., 2021), there is now greater consistency between the
guidelines available.
Recent publications have suggested defining a new condition, ‘pre-VITT’. This condition was
suggested on the basis that patients with VITT can present with elevated D-dimer levels,
thrombocytopenia and anti-PF4 antibodies before they develop thrombosis (Salih et al., 2021;
Makris and Pavord, 2022). Recognition of this condition would allow such patients to be
identified and treated quickly, reducing the chance that they will develop thrombosis. In such
cases where ‘pre-VITT’ is present, it is important that the condition is recognised and not
mistaken for other thrombocytopenic conditions such as thrombotic thrombocytopenic purpura,
immune thrombocytopenic purpura, or catastrophic antiphospholipid syndrome (Makris and
Pavord, 2022). Given that SARS-CoV-2 infection can also cause thrombosis, current COVID19 disease should also be ruled out in a patient presenting with symptoms suggestive of VITT.
It should also be determined whether the patient has recently received heparin treatment so as
not to mistake the condition for HIT (Elalamy et al., 2021).
RELATIONSHIP BETWEEN COVID-19 DISEASE AND THROMBOSIS
Infection with SARS-CoV-2 has been associated with several cardiovascular complications,
including thrombosis. Thrombosis commonly occurs in patients who develop severe COVID19
disease (Zhang et al., 2020). Some research has investigated whether there could be a shared
cause for the thrombosis seen in COVID-19 and in VITT, due to the fact that both involve the
expression of the spike protein of SARS-CoV-2 (McGonagle et al., 2021). In COVID-19
disease, viral RNA is the main cause of thrombosis although research has shown that the spike
protein may also be involved in immunothrombotic events. The spike protein acts via the
MAPK/ACE2 pathway (Zhang et al., 2020). Research has suggested that vaccination against
SARS-CoV-2 can promote the downregulation of ACE2 expression (Angeli et al., 2021),
proving it to be unlikely that ACE2 is involved in thrombotic events in VITT. Thus, there is
little evidence to support the suggestion that COVID-19 disease and VITT share the same cause
of thrombosis.
When it first emerged that there were thrombotic events associated with the administration of
the adenoviral vector vaccines, vaccine administration was paused in most countries to allow
research to be conducted into the link between the vaccines and thrombosis. Although the
AstraZeneca and Janssen vaccine programmes were both continued, the level of vaccine
hesitancy associated with the adenoviral vector-based vaccines was greater than that of the
mRNA based COVID-19 vaccines (Machingaidze and Wiysonge, 2021). One point which is
stressed across numerous research publications is that although there is a risk of thrombosis
associated with vaccination, the risk of thrombosis associated with infection by SARS-CoV-2
is far greater. On infection by SARS-COV-2, thrombosis is 100 times more likely to occur in
unvaccinated patients than in those who are vaccinated (Elalamy et al., 2021).
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PATHOGENESIS OF VITT
VITT is still a relatively new condition, so there are no reports which have definitively detailed
the mechanism by which the thrombotic thrombocytopenia is caused. It is likely that VITT has
an immunological mechanism like that of HIT. There are two forms of HIT, HIT which is
induced by heparin treatment and autoimmune or spontaneous HIT, which is not caused by
heparin treatment. VITT resembles autoimmune HIT closely. PF4 and anti-PF4 antibodies play
a pathological role in both VITT and HIT (Klok et al., 2021). In HIT, anti-PF4 antibodies bind
to platelet receptor FcγRIIA, causing platelet activation and thrombocytopenia (Elalamy et al.,
2021). Activation of platelets causes the release of PF4 from platelet alpha granules. Increased
levels of PF4 can cause endothelial activation which causes the recruitment of monocytes and
neutrophils. Monocyte sidechains can then bind with PF4 to create an immune complex which
will activate monocytes, stimulating their pro-coagulant activity. This in turn leads to the
expression of tissue factor and generation of thrombin, which further stimulates the activation
of platelets (Gaunt and Mabbott, 2021). This inflammatory response also involves the
activation of neutrophils, causing a process in which foreign pathogens are trapped, called
NETosis. This process releases leukocytic DNA, which promotes the formation of
microthrombi (Elalamy et al., 2021). A similar mechanism is predicted to occur in VITT, as
depicted in Figure 1. In VITT, the binding of the anti-PF4 antibodies occurs at a different
epitope than the binding site in HIT (Huynh et al., 2021). Platelet activation is reported to occur
through CD32a, which is a platelet membrane FcγRIIA receptor (Elalamy et al., 2021).

Figure 1 – Proposed pathogenesis of VITT (Klok et al., 2021).
In addition to the spike protein, vaccine components such as the adenoviral vector itself, the
viral capsid, free DNA, vaccine impurities, EDTA and other human proteins contained within
the vaccine have all been suggested as potential triggers for the response seen in VITT (Klok
et al., 2021). It has been shown that in the case of the AstraZeneca vaccine, the viral capsid can
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bind to spaces between the hexon proteins in PF4, allowing interaction between viral
components and PF4 (Baker et al., 2021). Before the emergence of VITT it was already known
that DNA can form complexes with PF4 which can bind to antibodies found in patients with
HIT (Greinacher, Thiele, et al., 2021). VITT appears to have an immune response involvement,
which may be triggered by EDTA, or other human proteins used in the vaccine (Greinacher,
Selleng, et al., 2021).
LABORATORY CONFIRMATION OF VITT
Reports on the laboratory indicators of VITT have been consistent since the condition was
identified. Indicators include thrombocytopenia, raised D-dimer levels, and in some cases low
fibrinogen levels and prolonged PT and aPTT. Platelet counts of ≤107x109/L, D-dimer levels
of ≤142mg/L and fibrinogen levels ≤2g/L are commonly observed in VITT patients
(Greinacher, Thiele, et al., 2021). Although these results are indicative of VITT, further testing
is required for diagnosis. VITT is characterised by the presence pf anti-PF4 antibodies, so
antiPF4 ELISA is commonly used as a diagnostic test. Anti-PF4 anti bodies have also been
found outside of VITT, with 5-7% of blood donors having detectable levels of anti-PF4
antibodies (Elalamy et al., 2021). Considering this, further testing is required to confirm that
the anti-PF4 antibodies detected in the suspected VITT patient are the cause of the platelet
activation and aggregation observed (Swan et al., 2021). Functional platelet activation assays
are often used for VITT confirmation after a positive anti-PF4 ELISA result is received (Klok
et al., 2021).
Anti-PF4 ELISA is commonly used for the detection of HIT antibodies but can be used for the
detection of VITT antibodies also (Kotal et al., 2021). The principle of the ELISA assay
involves the formation of PF4 and polyvinyl sulfonate (PVS) complexes, which are
immobilised on the surface of microwells. Anti-PF4 antibodies will bind to sites on the
PF4/PVS complexes, allowing their detection. The concentration of the anti-PF4 antibodies is
reported as an optical density (Mcfarland et al., 2012). Commonly used anti-PF4 ELISA tests
include Immucor, Hyphen and Stago assays, which have reported sensitivities of 100%, 92%
and 91% respectively when used for the detection of anti-PF4 antibodies in known positive
VITT patients (Swan et al., 2021).
Following a positive anti-PF4 ELISA result, a functional platelet activation assay should be
performed. Functional platelet activation assays for VITT have been developed based on assays
which are used for HIT diagnosis, including heparin-induced platelet activation (HIPA) assays,
and serotonin release assays (SRA) (Swan et al., 2021). The HIPA assay principle involves the
detection of platelet aggregation in the presence of heparin. The assay involves the visual
assessment of platelet aggregation within the reaction mixture, and a positive result is indicated
by the change in appearance from turbid to transparent. The SRA is based on the principle that
serotonin is released by the dense granules of platelets on activation by HIT antibodies. The
SRA involves the detection and quantification of serotonin released by patient platelets in the
presence of heparin (Minet, Dogné and Mullier, 2017). The utility of functional platelet
activation assays in the diagnosis of HIT has been well researched and documented.
These assays have been modified for use in the diagnosis of VITT by replacing heparin with
PF4 in both assays (Lavin et al., 2021). PF4-induced platelet activation (PIPA) assays have
been further modified to PF4-induced flow cytometry-based platelet activation (PIFPA) tests,
which are both used for the purpose of confirmation of a VITT diagnosis (Favaloro, 2021).
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PIPA assays have been reported to detected between 95 to 100% of VITT cases, making PIPA
a sensitive indicator of the condition (Lavin et al., 2021). HIPA and PIPA assays can in some
circumstances be used for the differential diagnosis of HIT and VITT, as the HIPA assay will
return a negative result in most VITT patients and most HIT patients will receive a negative
PIPA result (Lavin et al., 2021). The modified SRA has not been reported to show the same
sensitivity as the PIPA, with some research suggesting it is only 10% sensitive when used to
detect positive VITT cases (Swan et al., 2021). Both Anti-PF4 ELISA and PIPA assays are
currently performed by reference laboratories and not offered routinely in hospital laboratories.
TREATMENT OF VITT
The treatment of VITT generally involves two approaches. The patient must be treated for
thrombocytopenia, which generally involves intravenous immunoglobulin (IVIG) to recover
the platelet count. A form of anticoagulant should also be administered, regardless of whether
thrombosis has been identified in the patient or not (Pavord et al., 2021). This will reduce the
likelihood that patients who are in the proposed ‘pre-VITT’ stage will develop thrombosis. The
choice of treatment should be determined based on the severity of the symptoms experienced
by the patient. In cases of more serious illness, further treatment such as plasma exchange
should be considered and has been shown to be beneficial (Elalamy et al., 2021).
IVIG has been widely documented as one of the most common methods of treating
thrombocytopenia in VITT patients. IVIG inhibits the binding of anit-PF4 antibodies to the
FcγRIIA receptor, which prevents platelet activation and results in a rise in platelet count
(Bourguignon et al., 2021). IVIG administration should be combined with anticoagulant
treatment, to counteract or prevent thrombosis. Given that it is recommended to avoid heparin,
direct oral anticoagulants including fondaparinux, danaparoid and argatroban are commonly
used in VITT treatment. Some patients with VITT may experience excessive bleeding due to
thrombocytopenia, so different strategies to manage thrombosis should be considered for these
patients (Klok et al., 2021). For patients who are experiencing severe thrombocytopenia or
extensive thrombosis, plasma exchange should be considered. Mortality rates in VITT patients
increases with the presence of CVST and platelet counts of under 30x109/L, but plasma
exchange in such cases is associated with a 90% survival rate, making it a very favourable
treatment option (Pavord et al., 2021). Steroids and rituximab have also been reported to be
beneficial in settings of severe VITT (Klok et al., 2021).
CONCLUSION
While considerable research has been carried out on the clinical presentation and diagnostic
markers of VITT, there is still a lack of information on some aspects of the condition, including
how the vaccine triggers the thrombotic thrombocytopenia response observed. Initial research
reports published about VITT showed considerable variation in findings. Greater consistency
is seen in more recent publications, likely due to the accumulation of data about VITT as case
numbers of the condition have risen. Guidelines on the diagnosis of VITT have changed since
the condition was first recognised, and it is advisable that a set of guidelines which are updated
regularly should be used when diagnosing VITT, such as the recommendations set up by the
UK EHP.
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Recommendations for the treatment and management of VITT have been well-documented.
Although many cases of VITT are resolved with appropriate treatment, the fatality rate for the
condition is still very significant. This may be in part due to the fast progression of the
condition, making it difficult to make a diagnosis and start treatment before a patient becomes
considerably ill. The recognition of the proposed ‘pre-VITT’ stage could improve the overall
prognosis of the condition by increasing the chances of treating the patient before they have
developed thrombosis, which is the leading cause of fatality in VITT. Further research in this
area would be of benefit for the overall management of the condition. Expanding the
availability of Anti-PF4 ELISA and PIPA assays to hospital laboratories would lessen the time
between patient presentation and confirmation of diagnosis of VITT. Age is a known factor for
the condition, but further research into whether certain cohorts of individuals are more
susceptible to developing the condition, and the mechanism by which the vaccine triggers the
immune response seen in VITT would help in the prevention of serious illness.
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ABSTRACT
SARS Co-V2 virus outbreak has resulted in a worldwide pandemic causing the death of
approximately 5 million across the globe. The virus particle is transmitted via air droplets or
by direct contact with surfaces. Infected individuals may present with moderate flu-like
symptoms or may remain asymptomatic. While most cases of SARS Co-V2 resolve, some
patients may progress to acute respiratory distress syndrome (ARDS). The onset of ARDS is
associated with a broad range of complications leading to increased morbidity and mortality.
Sepsis induced coagulopathy is a clinically significant complication associated with the
development of ARDS. Approximately 3% of Covid-19 patients will progress to disseminated
intravascular coagulopathy, characterised by widespread hypercoagulation. The pathogenesis
of coagulopathy is inflammatory mediated and is associated with mass accumulation of
cytokines as seen in cytokine storms.
The aim of this literature is to evaluate the prognostic capability of haematological parameters
in SARS Co-V2 infection. While there is no definitive haematological pattern, the effect of
SARS Co-V2 infection on routine haematological tests is well documented. Approximately
80% of SARS Co-V2 patients present with lymphocytopenia, which may be accompanied by
inflammatory related alterations in the cellular population. Covid-19 induced coagulopathy can
be monitored using routine coagulation parameters. Poor prognostic outcomes are associated
with elevations in prothrombin time, fibrinogen, fibrin degradation products, and D-dimer
concentration. The degree of inflammatory mediated dysplasia seen in blood film examination
may be used to assess magnitude of immune system dysregulation and severity of respiratory
distress. A
panhaemocyometric approach examining leukocytes, erythrocytes and
thrombocytes is advisable considering SARS Co-V2 infection causes widespread alterations in
cellular morphology and number in cell populations.

KEYWORDS: SARS Co-V2 prognosis, complete blood count, advanced haematological tests,
coagulation tests, blood film
INTRODUCTION
Coronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses with
characteristic spike glycoproteins that radiate outward when visualized by electron microscopy
(Almeida and Tyrrell, 1967). There are four genera of Coronaviridae: alpha-, beta-, gamma-,
and delta-coronavirus; and in the context of human disease, alpha-coronaviruses and
betacoronaviruses can emerge from animal reservoirs as major pathogens (Ye et al., 2020).
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To date, there are seven coronaviruses associated with disease in man; four viruses,
hCoVHKU1, hCoV-OC43, hCoV-NL63 and hCoV-229E, cause asymptomatic or mild
respiratory and gastrointestinal infections, accounting for approximately 5–30% of common
colds (Pyrc et al., 2007). The remaining human coronaviruses – SARS-CoV-1, MERS-CoV,
and SARSCoV-2 – are recognised as highly pathogenic and potentially life-threatening agents (Chen et
al., 2020).
SARS-CoV-2, the causative agent of COVID-19, first emerged as an infectious agent of
concern in Wuhan, China in December 2019 (Huang et al., 2020). Since then, SARS-CoV-2
has spread rapidly and aggressively and was documented as a public health emergency of
international concern and a pandemic on 30th January and 11th March 2020, respectively (World
Health Organisation, 2021). As of 1st April 2022, SARS-CoV-2 infection has resulted in over
486 million cases of COVID-19 reported to the World Health Organisation, including over 6
million confirmed deaths (World Health Organisation, 2021).
COVID-19 is associated with a broad range of non-specific symptoms, including headache,
sore throat, and fever (Guan et al., 2020). SARS-CoV-2 utilises angiotensin converting enzyme
2 (ACE2) as a cellular entry receptor (Hoffmann et al., 2020), which is commonly found in
human epithelial tissue (Wong and Saier, 2021), enabling cellular attachment and cellular
infection. As infection progresses, the adaptive immune response is evoked leading to cytokine
and antibody response (Aleksova et al., 2021). Although most patients with COVID-19 are
either asymptomatic or present with moderate illness, many cases result in severe disease
warranting hospitalisation (Li et al., 2021). Patients with severe disease may develop
lifethreatening complications associated with the onset of acute respiratory distress syndrome
(ARDS) due to cytokine storms (Vinayagam and Sattu, 2020), in addition to acute kidney
injury, septic shock and multi-organ dysfunction (Liao et al., 2020).
Due to the labile natural history of COVID-19, it is critical that SARS-CoV-2 patients are
closely monitored, with those presenting with cytokine storm-associated ARDS of greatest
concern (Ragab et al., 2020). As such, laboratory testing is critical to diagnose patients with
SARS-CoV-2 infection, differentiate mild, moderate, and severe disease, and to evaluate
prognosis and recovery. The profound inflammatory response associated with COVID-19
appears to induce an aberrant haematologic and haemostatic system, characterised by abnormal
haematological parameters (Rahman et al., 2021). This review aims to examine the effect of
SARS-CoV-2 infection on traditional and novel haematological parameters, which could serve
as rapid diagnostic and prognostic indicators of SARS-CoV-2 infection, in conjunction with
molecular testing.
IMMUNE RESPONSE TO COVID-19 INFECTION
To understand the aberrant haematologic and haemostatic system of COVID-19, it is important
to address immune system activation in response to SARS-CoV-2 infection.
Innate immune response
SARS-Co-V 2 infection stimulates both an innate and adaptive immune response (Shi et al.,
2020). Pathogen pattern receptors, such as Toll-like receptors, are responsible for the
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recognition of the virus particle, which leads to expression of interferons, cytokines, and
chemokines (Perico et al., 2021). Activated macrophages are a critical feature of the
hyperinflammatory state seen in patients with COVID-19, with evidence to suggest direct viral
activation of macrophages in the peripheral circulation (Wang et al., 2020). Analysis of
bronchiolar lavage fluid reveals the presence of pro-inflammatory monocytes, infiltrative
neutrophils, and monocyte-derived macrophages (Bost et al., 2020; Zhou et al., 2020).
Activation of neutrophils, accompanied by the formation of neutrophil extracellular traps
(NETs), is associated with a heightened cytokine response, manifesting as a cytokine storm
(Barnes et al., 2020). As such, it appears an inappropriately exaggerated innate response
contributes the hyperinflammatory state in SARS-CoV-2 patients.
Adaptive immune response
SARS-CoV-2 infection elicits both T-cell- and B-cell-mediated lymphocyte responses (Chen
and Wherry, 2020; Röltgen and Boyd, 2021). Lymphopenia, characterised by reduction in the
absolute CD4+ and CD8+ lymphocyte count, is a common feature in COVID-19 patients
(Perico et al., 2021). T-cells display reactivity towards the spike glycoprotein of the virus
particle, suggesting the spike protein is the primary target for adaptive T-cell-mediated
response (Taborska et al., 2021). T-cell mediated response is typically rapid with CD4+ and
CD8+ cells identified 1 - 4 days post-onset of symptoms (Rydyznski Moderbacher et al., 2020;
Schulien et al., 2021). The CD4+ immune response appears to be more prominent than that of
the CD8+ in COVID-19 patients (Grifoni et al., 2020). CD4+ cells can differentiate into Th1
cells and T follicular helper cells (Tfh), responsible for production of inflammatory cytokines
and aiding the humoral response, respectively (Sette and Crotty, 2021). Rapid CD4+ response
is a positive prognostic factor for SARS CoV-2 patients, extended absence of these cells is
associated with increased severity and mortality (Braun et al., 2020). Similarly, the presence
an adequate CD8+ response is associated with better prognostic outcomes (Sette and Crotty,
2021). CD8+ lymphocytes are responsible for a variety of cytotoxic functions, such as the
release of IFN-γ, perforin, and granzyme B (Schulien et al., 2021).
B-lymphocyte immune response produce neutralising antibodies against the COVID-19
antigen (Röltgen and Boyd, 2021). The ACE2 receptor binding domain of the SARS-CoV-2
spike glycoprotein is highly immunogenic and stimulates a potent immune reaction, converting
naïve B cells to active antibody secreting B cells (Sette and Crotty, 2021). There is a correlation
between viral antigen titre and neutralising antibody titre, like other viruses of the
coronaviridae family, such as SARS Co-V and MERS (Sariol and Perlman, 2020). Several
monoclonal antibodies targeting epitopes seen on SARS Co-V virus particle, demonstrate cross
reactivity (Hoffmann et al., 2020). Initial humoral response comprises of IgA and IgM
antibodies, while IgG antibodies may be detected in the serum of SARS Co-V patients two
weeks following symptom onset (Guo et al., 2020). Rise in antibody titre is associated with
presence of plasma cells in the peripheral blood (Arashkia et al., 2021).
Role of traditional and advanced haematological parameters
Beckmann Coulter haematology analysers allow for advanced haematological testing based on
VCS technology, cells are characterised based on their volume, conductivity, and scatter (Vasse
et al., 2021). In addition to volume and conductivity there are several measures of scatter
employed by these analysers including median angle light scatter (MALS), lower median angle
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light scatter (LMALS), low angle light scatter (LALS) and upper median light scatter
(UMALS) (Jean et al., 2011). SYSMEX haematology analysers can be used to provide
necessary morphology details on leukocytes, enabling identification of altering leukocyte
morphology. These analysers discriminate cellular populations based on internal cellular
complexity, nucleic acid content and cell size (Urrechaga et al., 2021). Given that SARS-CoV2
infection stimulates an extensive immune response, and the magnitude of immune system
activation shows correlation with severity of respiratory distress, these advanced
haematological parameters could prove to be important prognostic tools for ARDS associated
with SARS-CoV-2 infection.
Effect on routine coagulation tests
Routine coagulation tests may be used as early indicators of coagulation defects associated with
SARS-CoV-2 infection (see Figure 1.1). Sepsis-induced coagulopathy is a serious complication
seen in patients with severe COVID-19 (Hosseini et al., 2021).

Figure 1.1 Comparison of the coagulation parameters of SARS Co-V2 patients and healthy
individuals (Han et al., 2020)
Prothrombin Time and Activated Partial Thromboplastin Time
Many studies report a prolongation of the PT in SARS-CoV-2 patients correlating with more
severe illness (Han et al., 2020; Huang et al., 2020; Wan et al., 2020), although other studies
report no significant difference between critical and non-critical cases (Gao et al., 2020; Wang
et al., 2020; Wu et al., 2020). Despite these findings, elevated PT is associated with increased
ICU admissions (Luo et al., 2020). Prolonged activated partial thromboplastin time (APTT)
may be indicative of increased risk for these patients (Wan et al., 2020; Wu et al., 2020),
although other studies report no significant increase or even a decrease in APTT in critical
COVID-19 cases (Tang et al., 2020; Wu et al., 2020). Thus, the association between APTT and
COVID-19 severity is complex and may rely on other factors. Many COVID-19 patients
admitted to hospital, present with PT and APTT values within the reference range of healthy
individuals, therefore baseline PT and APTT values have limited use as early prognostic
markers for coagulopathy in SARS-CoV-2 patients (Luo et al., 2020).
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Fibrinogen
There is conflicting evidence regarding fibrinogen as a prognostic marker for SARS-CoV-2
patients, although it is suggested that increased fibrinogen may be indicative of severe cases,
the significance of fibrinogen as an isolated prognostic marker of COVID-19 induced
coagulopathy is questionable (Han et al., 2020; Luo et al., 2020).
Fibrin degradation products
The concentration of fibrin degradation products is higher in COVID-19 patients than in healthy
individuals, with critical COVID-19 cases exhibiting the most elevated FDP concentrations
(Han et al., 2020). Thus, FDP may be used to monitor gradual progression of coagulopathy in
COVID-19. Although there is a positive correlation between increased FDP and the D-dimer
concentration, the D-dimer is a more specific marker of COVID-19-induced coagulopathy
(Asakura, 2014).
D-dimer concentration
D-dimer is a haematological parameter used to monitor the coagulation system, elevation in
this degradation product is indicative of activation of the coagulation system (Sathe and Patwa,
2014). Morbidities caused by SARS-CoV-2 infection have a greater likelihood of an increased
D-dimer concentration (Li et al., 2020). The D-Dimer concentration has been reported to
increase by as much as five-fold the upper limit of normal in those with severe respiratory
disease and is significantly greater than those with moderate respiratory illness (Huang et al.,
2020). SARS-CoV-2-induced activation of the coagulation system is associated with
pulmonary embolism (Vinayagam and Sattu, 2020). However, thrombosis is not limited to the
lungs; blood clots in the large arteria of the brain may lead to ischemic stroke (Qureshi et al.,
2021).
Disseminated intravascular coagulopathy (DIC) is characterised by widespread deposition of
fibrin in the coagulation system and has been highlighted as a potential complication associated
with SARS-CoV-2 infection (Asakura, 2014). Meta-analysis reveals approximately 3% of
COVID-19 patients develop DIC (Zhou et al., 2021). Although DIC is regarded as a systemic
coagulation disorder, it is possible that coagulopathy begins in the lungs in SARS-CoV-2
patients and spreads systemically to other organs (Magro, 2020). A significant elevation in
Ddimer concentration is observed in critically ill patients (Luo et al., 2020). Important markers
for coagulopathy are fibrin degradation products (FDP) and D-dimer (Hong et al., 2021).
COVID-19 patients suffering from coagulopathy may exhibit increased FDP and D-dimer
concentrations accompanied by prolonged prothrombin time (PT) and prolonged activated
partial thromboplastin time (APTT) (Han et al., 2020).
Patients with severe illness and markedly elevated D-dimer concentration may benefit from
treatment with low molecular weight heparin (LMWH) (Tang et al., 2020). Treatment with
heparin inhibits platelet aggregation and blood coagulation, thereby stalling the pathogenesis
of SARS-CoV-2-induced coagulopathy (Zhou et al., 2021). This therapy should however be
limited to patients meeting the criteria for coagulopathy and elevated D-dimer concentrations.
By monitoring the D-dimer concentration, it may be possible to assess the risk of a thrombotic
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event for patients with COVID-19 and to determine the possible eligibility of said patients for
anticoagulant therapy.
POTENTIAL AETIOLOGY OF COVID-19-INDUCED COAGULOPATHY
Cytokines have been identified as important mediators of the coagulation cascade (Levi et al.,
2003). In a cytokine storm, there is release of a broad range of cytokine such as IL-A, IL-B,
IL-6, IL-7, IL-8 and TNF-α (She et al., 2020). There is a correlation between increased IL-6
levels and serious complications associated with SARS-CoV-2 infection, this is as expected as
increased levels of IL-6 and IL-8 correlate with increased risk of coagulation events such as
venous thromboembolisms (VTEs) (van Aken et al., 2002). IL-6 induces the expression of
tissue factor, increases the expression of fibrinogen, factor VIII, von Willebrand’s factor (vWf)
and has been reported to reduce the expression of haemostasis inhibitors such as anti-thrombin
and protein S (Kerr et al., 2001). IL-6 STAT signalling has been identified as a potential cause
of acute respiratory syndrome through activation of cytokine storms (Zhou et al., 2020). IL-6
acts as an amplifier for inflammation causing increased levels of serum angiotensin II (Ang II),
and reduced expression of ACE2 due to interaction between the virus spike protein and ACE2
receptors (Hojyo et al., 2020). Ang II is a pro-inflammatory cytokine; Ang II increments are
associated with lung injury (Kuba et al., 2006). Therefore, it is plausible that Ang II could be
used as a predictive marker for SARS-CoV-2 severity (Hojyo et al., 2020). However, it is IL8
which displays the most prominent procoagulant activity activating thrombin, fibrin and
promoting platelet activation (Magro, 2020). Based on this evidence, it is possible to suggest
cytokine storms releasing inflammatory interleukins such as IL-6 and IL-8 may be responsible
for hypercoagulation events seen in COVID-19 patients.
As mentioned previously, COVID-19 infection elicits a hyperinflammatory state characterised
by cytokine storm-mediated organ damage. Despite this potent inflammatory response,
lymphocytopenia is a common feature amongst COVID-19 patients, contributing to increased
risk of mortality and morbidity (Vardhana and Wolchok, 2020). While cytokine stormmediated
coagulopathy is still believed to be the primary cause of SARS-CoV-2-induced ARDS,
depletion of lymphocytes leading to host cell immunity may also prove significant (Laterre et
al., 2020). COVID-19 patients with dramatically reduced lymphocyte counts demonstrate
impaired immune competence and are at greater risk of acquiring secondary infections (Ripa
et al., 2021). The importance of host immunity as a prognostic factor in SARSCoV-2 patients
is highlighted by IL-7 therapy, interleukin-7 (IL-7) contributes to increased lymphocyte
survival and expansion (Mackall et al., 2011). IL-7 therapy has demonstrated its importance in
increasing CD4+ CD8+ lymphocytes by 3-4-fold, contributing to restoration of the adaptive
immune response (Francois et al., 2018). Critical COVID-19 patients treated with IL-7 therapy
demonstrate a restored lymphocyte count without IL-7 contributing to increased
hyperinflammation and lung damage (Laterre et al., 2020). Thus, IL-7 therapy appears to be a
promising treatment option for SARS-CoV-2 patients exhibiting lymphocytopenia.
EFFECT OF ON LEUKOCYTE PARAMETERS
Granulocytes
Patients with COVID-19 typically present with neutrophilia and an increased
neutrophillymphocyte ratio (NLR) (Cavalcante-Silva et al., 2021). Cell population data
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parameters are emerging as novel indices of immune cell activation (Hoffmann, 2014; Harte
and Mykytiv, 2021). Sysmex XN-series analysers provide morphological and functional data
relating to the internal cellular complexity (SSC), nucleic acid content (FSL), and cellular size
(FSC) (Urrechaga et al., 2021). Neutrophil cell population data parameters, including NESSC, NEFSC, and NE-FSL, are significantly different in between COVID-19 patients and nonCOVID19 patients (Harte and Mykytiv, 2021; Pozdnyakova et al., 2021). However, these
results should be interpreted in the context of the peripheral blood film. The neutrophils exhibit
evidence of a reactive blood picture, containing cytoplasmic vacuoles, toxic granulation, and
heavily clumped chromatin (Singh et al., 2020). Cells indicative of a left shift in the myeloid
line, such as myelocytes and promyelocytes, may appear in a blood film (Vadillo et al., 2021).
The presence of immature erythroid and immature myeloid cells suggests a leucoerythroblastic
blood picture may be associated with SARS-CoV-2 infection (Mitra et al., 2020). Immature
granulocytes (IG), such as metamyelocytes, myelocytes and promyelocytes, can be used to
monitor the pathogenesis of sepsis; IG% of greater than 3% is linked with increased risk of
sepsis (Ayres et al., 2019). Thus, monitoring abundance of immature granulocytes in
SARSCoV-2 patients can monitor progression of sepsis and enable intervention (Jeon et al.,
2021). This is particularly relevant to critical COVID-19 cases which may progress to sepsis
and septic shock (Olwal et al., 2021). Reduced basophil count may be a poor prognostic feature
for SARS-CoV-2 patients due to their role in innate immune response; similarly, eosinopenia
may be associated with poorer patient outcomes (Sun et al., 2021; Xie et al., 2021).
Lymphocytes
Approximately 80% of SARS-CoV-2 patients display lymphocytopenia which may cause
leukocytopenia (Lee et al., 2021). Lymphocyte counts of less than 1 x 109 /L are associated
with SARS-CoV-2 patients suffering from severe respiratory disease (Singhal, 2020). Thus,
there is greater incidence of lymphocytopenia seen in COVID-19 patients admitted to ICU
(Ziadi et al., 2021). The reactive lymphocyte subset is largely comprised of
antibodysynthesizing lymphocytes, suggesting that the immune response to SARS-CoV-2
infection may be predominantly B-cell-mediated rather than T-cell (Linssen et al., 2020).
Increased activation of lymphocytes has been well documented in COVID-19 infection (Fan et
al., 2020). Sysmex XN-series analysers differentiate leukocytes according to fluorescent
properties, generating a leukocytic differential scattergram (Kawauchi et al., 2014). In COVID19, the lymphocyte clusters in the differential scattergram resemble an atypical ‘’sandglass’’,
this finding is suggestive of the presence of plasmacytoidal lymphocytes in the peripheral blood
(Osman et al., 2020).
These findings are consistent with evidence gathered from blood film examination. SARSCoV2 patients may exhibit atypical reactive lymphocytes or plasmacytoidal lymphocytes,
characterised by an eccentric nucleus and basophilic cytoplasm (Foldes et al., 2020). Large
granular lymphocytes may be present containing nuclei with condensed chromatin and
azurophilic cytoplasmic granules (Singh et al., 2020).
Monocytes
Initially these patients may present with monocytopenia followed by a subsequent monocytosis
(Singh et al., 2020). Patients with critical respiratory symptoms display monocytosis, with a
marked elevation in reactive monocytes seen (Linssen et al., 2020). Advanced haematology
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parameters reveal increased fluorescent intensity monocytes (MO-FSL) in COVID-19 patients
in comparison to non-COVID-19 patients, indicating these monocytes may be more
transcriptionally active (Pozdnyakova et al., 2021). In addition, patients with COVID-19 have
monocytes of increased intracellular complexity, as measured by an elevated MO-SSC score
on the Sysmex XN-series analysers (Harte and Mykytiv, 2021). Changes in this advanced
haematological parameter are present in 86% of COVID-19 patients (Harte et al., 2021
[unpublished]), and is the haematological parameter of greatest diagnostic utility at admission
(Harte and Mykytiv, 2021). Moreover, Beckmann Coulter haematology analysers allow for
advanced haematological testing based on VCS technology, whereby cells are characterised
based on volume, conductivity, and light scatter (Vasse et al., 2021). Changes in monocyte cell
population data on the Beckman Coulter series analysers, particularly the monocyte
distribution, has been shown to predict COVID-19 severity (Ognibene et al., 2020; Vasse et
al., 2021).
Large atypical, activated monocytes have also been reported in the peripheral blood of
COVID19 patients, these cells are CD90+ CD206+, indicating they are inflammatory
monocytes (Zhang et al., 2021). The peripheral blood of SARS-CoV-2 shows significant
expansion of CD14+CD16+ monocytes which as responsible for producing IL-6 (Y. Zhou et
al., 2020). The monocytic nuclei are large with condensed chromatin, monocytes may display
granulation and prominent cytoplasmic vacuolisation (Singh et al., 2020). Large, atypical
monocytes are indicative of monocyte activation and accumulation of inflammatory cells as
seen in a cytokine storm (Vanderbeke et al., 2021). Blue-green cytoplasmic inclusions within
monocytes and/or neutrophils have been reported in Covid-19 patients (Cantu et al., 2020).
Such neutrophilic inclusions were previously associated with acute hepatic failure and
multiorgan failure, contributing to significant morbidity and mortality (Soos et al., 2019).
Although the pathogenesis of blue-green inclusions within neutrophils and monocytes is not
fully understood, presence of such inclusions is indicative of poor prognostic outcome in
Covid-19 patients (Cantu et al., 2020).
Analysis of bronchoalveolar fluid highlights an increased proportion of mononuclear
phagocytes, cells which are associated with SARS-CoV-2 inflammation (Kvedaraite et al.,
2021). This is accompanied by a reduced count of tissue resident macrophages and presence of
inflammatory macrophages derived from monocytes (Merad and Martin, 2020). Accumulation
of neutrophils and myeloid cells in the lung may be indicative of local inflammation associated
with acute lung injury (Rodriguez et al., 2020).
EFFECT ON ERYTHROCYTE PARAMETERS
Hospitalized SARS-CoV-2 patients exhibit a reduction in haemoglobin concentration, typically
critical cases and non-critical cases can be differentiated by a marked reduction in haemoglobin
concentration in critical cases after day 5 of hospitalisation (Linssen et al., 2020). Critical
SARS-CoV-2 patients exhibit an increased reticulocyte response after day 7 of hospitalisation
in comparison with non-critical SARS-CoV-2 patients, a sharp increase in NRBC is seen in
critical cases during this period (Linssen et al., 2020). Increased NRBC in the peripheral blood
of SARS-CoV-2 patients is indicative of bone marrow stress (Purtle et al., 2017). The
prevalence of nucleated red cells in the peripheral blood may be used as prognostic tool to
access risk of mortality associated with ARDS (Menk et al., 2018). Although the underlying
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cause of NRBC release into the peripheral blood of ARDS patients is not fully understood, it
is believed systemic inflammation and arterial hypoxemia are triggering factors (Danise et al.,
2011). Mushroom shaped erythrocytes known as Pincer cells have been reported in the
peripheral blood of COVID-19 patients (Gérard et al., 2021). These cells are indicative of
oxidate stress and are also seen in cases of Protein Band 3 deficiency as seen in hereditary
spherocytosis (Gérard et al., 2021). The pathophysiology of SARS-CoV-2 infection involves
oxidative stress induced cytokine storm, which may cause damage to the erythrocytes, altering
their morphology see figure 1.2 (Dienstmann et al., 2021).

Figure 1.2 Pincer erythrocyte in the peripheral blood of a SARS CO-V2 patient
(taken from Deinstmann et al 2021).

Effect on platelet parameters
The correlation between disease severity and platelet count is not clear, with reports presenting
conflicting evidence regarding its use as a prognostic marker (Luo et al., 2020; Wan et al.,
2020). Initially, COVID-19 patients may present with platelet counts within the reference range
of a healthy individual (Harte and Mykytiv, 2021). Many ARDS patients suffer from
thrombocytopenia characterised by a platelet count <140 x 109/L, this may be followed by
reactive thrombocytosis where there is further elevation in the platelet count (Wong et al.,
2003). This may help to explain the fluctuation in platelet count associated with ARDS, and
the inconsistent reports on the utility of platelets as prognostic markers. Based on this evidence,
using platelet counts alone may not be appropriate for monitoring coagulopathy associated with
COVID-19-induced ARDS. SARS-CoV-2 patients display thrombosis, with hospitalisation
cases demonstrating an elevated platelet-lymphocyte ratio (PLR) outside the typical range
(Linssen et al., 2020).
CONCLUSION
Deviations in the cellular population are evident across all cell lines, thus it is advisable to adopt
a panhemocytometric approach when considering prognosis SARS Co-V2 patients. Although
haematological tests may serve as prognostic tools for SARS Co-V2 patients, prognosis may
vary based on a wide range of parameters such as demographic factors relating to patient age,
gender, smoking and patient history factors referring to patient’s underlying conditions
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(Patanavanich and Glantz, 2021; Zandkarimi et al., 2022). Thus, these factors should be
considered when accessing prognostic outcome. Increased or prolonged coagulation tests may
be utilised to monitor pathogenesis of COVID-19 induced coagulopathy. Monitoring such
patients enables earlier intervention and enhanced prognostic outcomes. The aetiology of
SARS Co-V2 induced coagulopathy is mediated by atypical cytokine storms. Advanced
haematological parameters enable characterisation of activated and reactive cells, thus
accessing the magnitude of immune dysregulation, which offers prognostic utility. These
parameters may be interpreted in conjunction with cellular morphology seen in blood film
examination. Alterations in cell number, typically characterised by lymphocytopenia and
increased neutrophil:lymphocyte ratio offer prognostic value for SARS Co-V2 patients.
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ABSTRACT
The first descriptions of haemophilia A were reported in the second century AD, with the first
modern description by John Conrad Otto in 1803. Historically, the natural history of
haemophilia A was associated with very high rates morbidity and mortality, often following
trivial accidents. Although treatment options for haemophilia A have been revolutionised in
recent decades, haemophilia A remains a hereditary disease of concern and factor replacement
products remain the mainstay of treatment.
As such, patients with haemophilia can carry huge burdens, particularly when a complication
such as a FVIII inhibitor is present. A recently approved novel therapeutic, Emicizumab-kxwh,
has offered an unexpected and alternative approach to haemophilia A therapy. This
recombinant, humanized, bi-specific antibody provides patients with effective haemostasis,
empowerment of self-administration, and an overall improved quality of life. For patients with
FVIII inhibitors, Emicizumab-kxwh offers a simple treatment mechanism that can efficiently
overcome deleterious antibodies as the antibody bridges FIX and FX, mimicking the function
of FVIII without sharing structural homology or biochemical properties. Considering this, the
literature and clinical trials available to date have been critically analysed and discussed herein.
This review aims to explore the advantages, disadvantages, and any potential need for caution
with Emicizumab-kxwh.
INTRODUCTION
Haemophilia A is an X-linked coagulation disorder characterised by quantitative or qualitative
defects in coagulation factor VIII (FVIII), also known as the antihaemophilic factor. This
disorder is thought to have been reported as early as the second century AD (Franchini and
Mannucci, 2014). However, modern descriptions were observed in the 1800’s when it was
noted that males from the same family (known as ‘bleeders’) suffered from several bleeding
events with apparent asymptomatic female transmission (Schramm, 2014). The disease was not
well understood at the time, but it was determined that males should not be circumcised if two
brothers of the family had already died from excessive bleeding following the procedure
(Franchini and Mannucci, 2014). The Babylonian Talmud indicates that if a woman has lost
her first two sons after circumcision, she is exempt from the obligation to have the third son
circumcised (Rosendaal, Smit and Briët, 1991). Haemophilia is commonly referred to as the
royal disease, as Queen Victoria was a carrier of Haemophilia B which lead to several royal
family members being affected by the disease (Franchini and Mannucci, 2014). One of the first
clinically accurate descriptions of haemophilia A was reported in 1803 by John Conrad Otto.
His understanding of the disease was “if least scratch is made on the skin of some of them, as
mortal a haemorrhage will eventually ensue.” He also was capable of observing the inheritance
pattern by stating that “it is a surprising circumstance that the males only are subject to this
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strange affection, and that all of them are not liable to it” (Otto, 1803). The first descriptions
of the genetics of haemophilia were published in 1820 by Nasse culminating in Nasse’s law,
which states that haemophilia is transmitted entirely by unaffected females to their sons (Nasse,
1820).
Today, haemophilia A can be classified based on the severity of the FVIII deficiency present.
Patients with mild haemophilia present with 5 - 40% of normal FVIII levels (>0.05-0.4 IU/mL);
moderate haemophilia A with 1-5% of normal FVIII levels (0.01-0.05 UI/mL); and, severe
haemophilia A with <1% of normal FVIII levels present (<0.01 IU/mL) (Bolton-Maggs and
Pasi, 2003). Approximately 50-60% of patients with haemophilia A present with severe
disease.
The qualitative or quantitative defects in coagulation FVIII observed in haemophilia A are
hereditary. Genetic mutations in the FVIII gene, found on the long arm of the X chromosome
at position Xq28, are responsible for this hereditary disease. Although more than 2800 different
mutations of the F8 gene are documented in the Human Gene Mutation Database, the most
common mutation identified in haemophilia A is the intron 22 inversion (Inv22) of the F8 gene,
observed in 45% of severe haemophilia A patients (Bolton-Maggs and Pasi, 2003). Inv22 is a
result of homologous intrachromosomal recombination between the F8A gene in intron 22 and
two additional transcribed copies of the F8A gene telomeric and upstream to the F8 gene
(Lakich et al., 1993; De Brasi and Bowen, 2008). While this is a hereditary disorder, it is
noteworthy that Srivastava et al., (2020), report that approximately 30% of cases of
haemophilia, including instances of haemophilia B, arise as a result of spontaneous genetic
variants.
The clinical significance of Haemophilia A is demonstrated by the spontaneous bleeding
episodes often encountered by these patients. Haemophilia A patients (particularly those with
these severe type), can suffer bleeding into joints (haemarthrosis) and soft tissues, muscle
haematomas, gastrointestinal bleeding, central nervous system bleeding and excessive bleeding
following trauma or surgery (Mansouritorghabeh, 2015; Srivastava et al., 2020) Haemarthrosis
is characteristic of the severe form of haemophilia A and is most seen in the knees, elbows,
ankles and wrists (Mansouritorghabeh, 2015). Both haemarthrosis and muscle haematomas can
lead to restricted movements in the joints and limbs affected (Mansouritorghabeh, 2015).
Historically, these episodes could even be fatal for the patient as there were little or no treatment
options available (Schramm, 2014). In the 1950’s and 1960’s, patients could be treated with
fresh plasma. However, this form of therapy did not offer sufficient FVIII to treat serious
bleeds, and fatalities were common (Franchini and Mannucci, 2014). At the time, this plasma
was not treated with pathogen reduction techniques. Subsequently, many mortalities were seen
because of human immunodeficiency virus (HIV) infection and hepatitis virus infections
(Franchini and Mannucci, 2014).
However, today there are several safe treatment options available for haemophilia A patients.
The most common treatments utilised are recombinant FVIII concentrates that have been
available since the 1990s (Casademunt et al., 2012). These FVIII concentrates act as a
replacement for the deficient or defective physiological FVIII. These have been successful in
reducing the rate of bleeding in haemophilia A patients by 90% (Morfini and Marchesini,
2020). Despite their success, these FVIII concentrates have still been associated with
breakthrough bleeding when used as a prophylaxis. The annual bleeding rate (ABR) for patients
using FVIII concentrates as a prophylaxis varies from 0-11.8 events per annum (Sun et al.,,
2021). A study conducted by Musso et al., 2008, observed that 65.7% of patients (mainly with
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severe haemophilia A) using FVIII concentrates as prophylaxis experienced some form of
spontaneous bleeding. However, this study also reports that 85.4% of bleeding events can be
successfully treated with one or two infusions of FVIII concentrates. The most notable issue
associated with these FVIII concentrates is the development of antibodies/inhibitors against
them. Twenty percent of haemophilia A patients will develop an inhibitor against FVIII
concentrate treatments, mainly in patients with severe haemophilia A (Walsh et al. , 2015;
Paisley and Wight, 2003). These inhibitors can render treatment 2-3 times more expensive by
comparison to those who do not develop an inhibitor (Guh et al., 2012). More clinically
significant, the presence of inhibitors means that bleeding episodes are more difficult to prevent
and treat using FVIII concentrates.
With the above taken into consideration, FVIII concentrates have provided a considerable
treatment option for haemophilia A patients. However, their drawbacks revealed a space on the
market for a more efficient drug with a potentially easier administration. The relatively new
bispecific antibody emicizumab-kxwh (HEMLIBRA, Genentech, Inc.) meets these
requirements.

PHARMACODYNAMICS OF EMICIZUMAB-KXWH
The function of active FVIII (FVIIIa) in vivo is to act as a non-enzymatic cofactor for FIXa for
the activation of FX in the presence of phospholipids and calcium ions (Mazurkiewicz-Pisarek
et al., 2016). This is part of the intrinsic coagulation pathway that leads to further activation of
prothrombin to thrombin and subsequently allow for clot formation when fibrinogen converts
to fibrin. Therefore, in haemophilia A, this mechanism is decreased or lost.
Emicizumab-kxwh (sold under the brand name HEMLIBRA) developed by Genentech, Inc. is
a bispecific antibody that binds to both FIXa and FX, allowing it to mimic the function of FVIII
to maintain haemostasis (Kitazawa et al., 2017). The function of the antibody is based on the
mechanism by which FVIIIa interacts with both FIXa and FX, as shown Figure 1 (Kitazawa et
al., 2017). Despite mimicking the function of FVIII, emicizumab-kxwh does not display
structural homology with physiological FVIII or FVIII concentrates. This property allows it to
evade the immunogenicity of inhibitors against FVIII that may be present in haemophilia A
patients (Le Quellec and Negrier, 2018). FVIII and emicizumab-kxwh also have different
biochemical properties (Müller et al., 2019). Emicizumab-kxwh binds specifically to the EGF1
domain of FIXa and the EGF2 domain of FX, despite this domain being present in other vitamin
K dependent factors (European Medicines Agency, 2018).
The route of administration for emicizumab-kxwh is subcutaneous (Yoneyama et al., 2018)
which is advantageous over intravenous administration (as seen with FVIII concentrates) as it
allows for self-administration (Le Quellec and Negrier, 2018). There are a variety of dosing
regimens available (1.5 mg/kg, 3 mg/kg or 6 mg/kg) which means emicizumab-kxwh can be
administered weekly, fortnightly or monthly (Blair, 2019). This is highly convenient rather than
administering intravenous FVIII concentrates two to three times per week, depending on the
dosing regimen of FVIII required (Srivastava et al., 2020). However, this strict regimen is
necessary for FVIII concentrates due to their short half-life (Parisi and Kumar, 2021). In
contrast, emicizumab-kxwh has a half-life of approximately 30 days and a high bioavailability
following subcutaneous administration (Yoneyama et al., 2018).

30

Volume 2 Issue 1

IUJHS

06/2022

(a)

(b)

(c)

Figure 1: (a) Schematic representation of the mechanism of action of emicizumab-kxwh in the
physiological coagulation cascade. (b) Mechanism of action of physiological FVIII in vivo.
(c) Mechanism of action of emicizumab-kxwh. Adapted from BioRender.com
(https://biorender.com/).
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EFFICACY OF EMICIZUMAB-KXWH
Several studies have been conducted on the efficacy and safety of Emicizumab-kxwh in patients
see table 1. HAVEN 1 successfully demonstrates that emicizumab-kxwh is capable of
significantly reducing the ABR in comparison to haemophilia A patients receiving no
prophylaxis. The ABR for treated bleeds was 2.9 in those receiving 1.5 mg/kg per week
whereas the ABR for those receiving no prophylaxis was 23.3, an increase of 87% (Oldenburg
et al., 2017). However, most haemophilia A patients will receive some form of treatment so
those receiving no prophylaxis do not fairly represent the ‘normal’ population. It was
interestingly noted that participants in this trial who had previously been treated with episodic
bypassing agents had an ABR of 37.7 (21.6 of which were treated bleeds). This then decreased
to an ABR of 4.1 (1.7 of which were treated) when using emicizumab-kxwh. These ABR values
were obtained in the first 24 weeks of the trial, and significant changes were seen in the long
term. After one year of using emicizumab-kxwh, the ABR for participants was 0.6, 0 of which
were treated bleeds (Oldenburg et al., 2017). This indicates that emicizumab-kxwh may be a
more effective prophylaxis in the longer term.
HAVEN 2 reported similar findings regarding the efficacy of emicizumab-kxwh in paediatric
patients with inhibitors. However, this study investigated different dosing regimens of the drug
and found that 3 mg/kg per 2 weeks appeared to be the most efficient. Participants receiving 3
mg/kg per 2 weeks had an ABR of 1.5 (0.2 of which were treated). Those receiving 6 mg/kg
per 4 weeks had an ABR of 3.8 (2.2 of which were treated) and those receiving 1.5 mg/kg per
week had an ABR of 3.2 (0.3 of which were treated) (Young et al., 2019). However, caution
should be taken when interpreting these ABRs as the higher ABR reported in the group of
participants receiving 6 mg/kg per 4 weeks was primarily associated with two participants: one
had several joint bleeds, and the other participant developed anti-drug antibodies (ADA).
Interestingly, these ADAs had neutralising potential and there was very little emicizumabkxwh
detectable in this participants bloodstream (Young et al., 2019). In total, four participants
developed ADAs as part of HAVEN 2. Two of these participants had ADAs without
neutralising potential, which did not have any effect on the efficacy of the drug. However, the
other two participants developed ADAs with neutralising potential. One of these participants
had to drop out of the study with many bleeding events reported (as mentioned above).
However, the other participant had decreased (but still detectable) levels of plasma
emicizumab-kxwh. This participant had a ‘normal’ APTT and reported no bleeding events
throughout the study, despite the presence of ADAs with neutralising potential. Follow up after
the study showed that this participant had become ADA-negative and normal plasma
emicizumab-kxwh levels were reported (Young et al., 2019). To date, no clear predisposing
factors for the development of ADAs in these participants has been identified.
Unlike HAVEN 1 and HAVEN 2, HAVEN 3 studied the efficacy of emicizumab-kxwh in
participants without inhibitors. All participants of this study had previously received
prophylactic or episodic FVIII concentrates (Mahlangu et al., 2018). This study showed similar
findings to HAVEN 1 as 56% and 60% of participants receiving 1.5 mg/kg per week and 3
mg/kg per 2 weeks, respectively, had no treated bleeding events whereas all participants (n=18)
receiving no prophylaxis reported treated bleeds in the first 24 weeks of the study. HAVEN 1
showed that there was an 87% increase in treated bleeds when receiving no prophylaxis
compared to when receiving emicizumab-kxwh in the first 24 weeks of the study. This study is
a useful comparison of emicizumab-kxwh and FVIII concentrates efficacy as it includes
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intraindividual analysis. Mahlangu et al., (2018), report that the ABR decreased by 68% when
a participant moved from FVIII prophylaxis to emicizumab-kxwh prophylaxis.
HAVEN 4 was a smaller study that focused on the 6 mg/kg per 4 weeks dosing regimen in
mainly adult participants. This study reported that the ABR for participants after 24 weeks of
emicizumab-kxwh was 4.5 (2.4 of which needed to be treated) (Pipe et al., 2019). Interestingly,
this study also states that 100% of the participants prefer emicizumab-kxwh over their previous
treatment of intravenous FVIII (Pipe et al., 2019).
While other studies were and continue to be carried out, the results obtained in HAVEN 1,
HAVEN 2, HAVEN 3 and HAVEN 4 were vital in the approval of this drug for routine
prophylactic use, as they were the largest clinical trial programmes for haemophilia A to date
(Young et al., 2019). Additional studies include HAVEN 5, HOHOEMI (Shima et al., 2019)
and STASEY. Results observed in the HOHOEMI study correlate with other paediatric studies
such as HAVEN 2 and confirm the safety of emicizumab-kxwh for routine use. The HOHOEMI
study also revealed that participants could participate in physical activity with moderate or high
risk while maintain a low ABR (Shima et al., 2019). Historically, high risk physical activity
was a risk for haemophilia A patients and activities such as swimming, walking, rowing,
sailing, and table tennis were encouraged (Srivastava et al., 2020).
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Table 1: Summary of Emicizumab-kxwh clinical trials
Name
study

of Participants
enrolled

Emicizumabkxwh Number of Current
dose investigated participants status

References

HAVEN 1

Adults
and 1.5 mg/kg per
adolescents
week
with inhibitors

109

Completed (Oldenburg
et al., 2017)

HAVEN 2

Children with
inhibitors

88

Completed (Young
et
al., 2019)

HAVEN 3

Adults
and 1.5 mg/kg per
week
adolescents
3 mg/kg per 2
without
weeks
inhibitors

152

Active, not (Mahlangu
recruiting et al., 2018)

HAVEN 4

Adults
and 6 mg/kg per 4
adolescents
weeks
with
or
without
inhibitors

41

Active, not (Pipe et al.,
recruiting 2019)

HAVEN 5

Adults
and 1.5 mg/kg per
week
adolescents
with
or 6 mg/kg per 4
weeks
without
inhibitors

70

Active, not No
results
recruiting available

13

Completed (Shima
et
al., 2019)

193

Completed (HoffmannLa
Roch
e,
2021a)

HOHOEMI Children
without
inhibitors
STASEY
(Safety
study)

1.5 mg/kg per
week
3 mg/kg per 2
weeks
6 mg/kg per 4
weeks

3 mg/kg per 2
weeks
6 mg/kg per 4
weeks

Adults
and 1.5 mg/kg per
adolescents
week
with inhibitors

CURRENT GUIDELINES FOR THE USE OF EMICIZUMAB-KXWH
Emicizumab-kxwh is a relatively new haemophilia A therapy and has only been approved for
routine use in recent years. Emicizumab-kxwh is Food and Drug Administration (FDA)
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approved for routine prophylaxis in adult and paediatric patients with congenital haemophilia
A and with inhibitors since November 2017, and without inhibitors since October 2018 (U.S.
Food & Drug Administration, 2018). In Europe, the drug is approved for use by the European
Medicines Agency (EMA) in haemophilia A patients with inhibitors since February 2018 and
for patients with severe haemophilia A without inhibitors since January 2019 (Krumb et al.,
2021).
With three dosing regimens of emicizumab-kxwh available, there are variations seen between
countries on the guidelines employed. The World Haemophilia Federation recommend that
emicizumab-kxwh should be used for haemophilia A patients with an inhibitor and can be used
for patients without an inhibitor (Srivastava et al., 2020). Most countries recommend a loading
dose of 3 mg/kg per week for four weeks, followed by a maintenance dosing regimen
(Hoffmann-La Roche, 2021; European Medicines Agency, 2018). The maintenance dose is
often based on physician and patient / caregiver preference in terms of adherence to the regimen
(Holstein et al., 2020). However, some countries have individual dosing recommendations for
certain patient cohorts. For example, in Canada, all three dosing regimens (1.5 mg/kg per week,
3 mg/kg per 2 weeks and 6 mg/kg per month), are available. However, the 6 mg/kg per 4 weeks
regimen is not recommended for paediatric patients or patients weighing <40 kg (HoffmannLa
Roche, 2021). In contrast, the FDA recommend the standard loading dose followed by 1.5
mg/kg per week in the USA (U.S. Food & Drug Administration, 2017). In Ireland, the Health
Products Regulatory Authority has authorised the use of 150 mg/ml and 30 mg/ml solutions
that can be used to administer dosing regimens of 1.5 mg/kg per week, 3 mg/kg per two weeks
or 6 mg/kg per four weeks (Irish Haemophilia Society, 2021).

LABORATORY TESTING FOR PATIENTS ON EMICIZUMAB-KXWH
FDA and EMA approval of emicizumab-kxwh will inevitably lead to an increase in patients
using the drug in the future. This novel drug will likely inflict challenges in clinical laboratories
associated with the monitoring of these patients (Srivastava et al., 2020). Tests that have been
shown to be affected by this drug include the activated partial thromboplastin time (APTT), the
Bethesda clotting-based assay, APTT-based factor assays and activated protein C resistance
assays. As expected, prothrombin time (PT) assays, thrombin time (TT) and chromogenic
factor assays using bovine coagulation factor reagents remain unchanged in haemophilia A
patients prescribed emicizumab-kxwh (Mahlangu et al., 2018).
The APTT is a two-stage assay that can be used as a screening test for haemophilia A and other
coagulation disorders, as well as an assay to monitor drugs such as unfractionated heparin
(Lippi and Favaloro, 2019). It is a simple and cost-efficient assay that has easily lent itself to
automation (Ignjatovic, 2013). The principle of the assay involves detection of a fibrin clot
once the coagulation cascade of patient plasma has been activated by a FXII activator and
calcium chloride. The results are reported in seconds, which is the time to clot formation
(Ignjatovic, 2013). This should be carefully interpreted in patients with a haematocrit >55%,
which is common in paediatric patients, as these patients have a decreased plasma volume, and
the APTT may be increased consequently (Srivastava et al., 2020). In this situation, the bloodto-anticoagulant ratio may need to be altered for accurate results.
Since haemophilia A affects FVIII, haemophilia A patients generally have a prolonged APTT
(Srivastava et al., 2020). In theory, emicizumab-kxwh should affect the results of any assay
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that measures FIX or FX. Patients using emicizumab-kxwh have been reported to have a
shortened APTT, some even within the ‘normal’ range (Bowyer, Kitchen and Maclean, 2020).
This shortened APTT can be seen for as long as 6 months post emicizumab-kxwh treatment
due to the long half-life of the antibody (Uchida et al., 2016). Haemophilia A patients using
FVIII concentrates also experience a shortened APTT result. However, the shortening affect
caused by emicizumab-kxwh is more pronounced and can be evident with subtherapeutic levels
of emicizumab-kxwh because emicizumab-kxwh does not require activation for function as
FVIII concentrates do (Shimonishi et al., 2020; Srivastava et al., 2020).
Despite the widespread use of the APTT assay in laboratories, shortcomings are seen in terms
of standardisation. Unlike the prothrombin time assay, the APTT is reported in seconds,
regardless of what reagents are used. This can lead to varying results between laboratories and
subsequently, results can be difficult to interpret (Ignjatovic, 2013). An example of this was
seen when the APTT of several patients using emicizumab-kxwh was analysed using different
reagents namely Actin, Actin FS, Actin FSL, Pathromtin SL, Synthasil, Synthafax, APTT SP,
STA- PTTA, Cephascreen, CK Prest, Triniclot APTT S, Triniclot ATT HS and Triniclot APTT
Auto. The APTT results obtained varied, with only eight out of thirteen reagents displaying a
constant ‘normal’ APTT (Bowyer, Kitchen and Maclean, 2020). For this reason, the variability
in reagents used in the APTT assay should be considered.
The Bethesda clotting-based assay is a useful method to identify the presence of FVIII
inhibitors in haemophilia A patients. However, as this is a clotting-based assay, the results are
affected by emicizumab-kxwh. Therefore, the World Federation of Haemophilia recommend
that inhibitor levels in emicizumab-kxwh patients should be identified and monitored via a
chromogenic Bethesda assay using bovine reagents (Srivastava et al., 2020). Bovine reagents
are necessary to prevent cross reactivity with emicizumab-kxwh. Bethesda assays involving
human proteins should be restricted to patients not prescribed this drug (Lippi and Favaloro,
2019). Furthermore, FVIII plasma levels are important for haemophilia A patients and may
need to be regularly monitored. When a patient is taking a drug such as emicizumab-kxwh, an
APTT-based factor assay cannot be used for plasma FVIII levels and a chromogenic assay is
necessary (Krumb et al., 2021).
There are suggestions that there is little need to monitor patients using emicizumab-kxwh by
laboratory testing. However, there are concerns that there are risks of procoagulant activity in
patients using this drug, who have a breakthrough bleed and are then prescribed other
procoagulants, such as activated prothrombin complex concentrate (aPCC) (Hartmann et al.,
2018). In the HAVEN 1 trial, two patients experienced thrombotic microangiopathy (TMA)
when treated with >100 U/kg of aPCC daily for more than one day after experiencing a
breakthrough bleed while using emicizumab-kxwh (Oldenburg et al., 2017). This is because
aPCC increases the availability of FIX and FX, resulting in increased thrombin generation and
exaggerated procoagulant activity (Hartmann et al., 2018). These findings suggest that there
should potentially be a standardised monitoring system in place for patients using emicizumabkxwh in the event of a breakthrough bleed.
The traditional APTT is not recommended for monitoring of Haemophilia A patients prescribed
Emicizumab-kxwh because the drug does not provide a true reflection of the coagulation
cascade in vivo, as emicizumab-kxwh does not require activation by other coagulation factors
(Adamkewicz et al., 2020). Most clinical trials involving emicizumabkxwh employed an
ELISA assay to monitor plasma Emicizumab-kxwh levels (Adamkewicz et al., 2020).
However, this is a complex assay that would not be suitable for routine clinical laboratory use
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(Kitazawa et al., 2017). With the clear demand for a reliable clinical assay for the measurement
of emicizumab-kxwh activity, a modified APTT-based FVIII one step assay (OSA) has been
developed (Calhoon et al., 2018, as cited by Müller et al., 2019). This assay has been calibrated
against emicizumab-kxwh and has a higher patient dilution than the traditional APTT-based
FVIII assay (allowing a larger range of emicizumab-kxwh monitoring). Other than this
modification, the assay follows the same principle as the traditional APTT-based FVIII assay
and has been in use commercially in Austria, Germany, and Switzerland. The World
Haemophilia Federation recommend the use of this assay for the monitoring of emicizumabkxwh in patients when necessary (Srivastava et al., 2020). Adamkewicz et al., 2020, found that
this OSA displayed similar emicizumab-kxwh plasma levels when compared to the
complicated and non-commercial ELISA assay employed in the HAVEN clinical trials.
The above demonstrates that there is a possible mechanism of routinely measuring
emicizumab-kxwh activity and patient FVIII plasma levels. However, obstacles may remain
for the analysis of other coagulation factors measured by the APTT assay (FIX, FXII and
FXIII).

BENEFITS OF EMICIZUMAB-KXWH FOR HAEMOPHILIA A PATIENTS
Clinical trials to date illustrate the value of emicizumab-kxwh for haemophilia A patients. This
drug has revolutionised treatment, despite experts expecting gene therapy to be the next step
for haemophilia A (Morfini and Marchesini, 2020). While FVIII concentrates still offer a
substantial prophylactic option, emicizumab-kxwh has demonstrated itself as far superior with
many advantages, primarily the decreased ABR associated with it.
While analysis of the ABR is vital for understanding the efficacy of emicizumab-kxwh, the
quality of life for the patient is also an important factor to consider. The HAVEN 1 study
conducted by Oldenburg et al., 2017, used numerical values to assess the quality of life as
reported by the participants in the trial, with the lower scores indicating a better quality of life.
Those receiving 1.5 mg/kg of emicizumab-kxwh per week had a score of 30.19, while those
receiving no treatment had a score of 57.14 (). Scores were calculated based on answers given
by patients in a questionnaire given to haemophilia A patients prescribed emicizumab-kxwh.
Self-administration of emicizumab-kxwh is hugely advantageous for haemophilia A patients as
it avoids intravenous administration by a healthcare professional two to three times per week
(Pipe et al., 2019; Srivastava et al., 2020) allowing haemophilia A patients to become
competent in their own care. Should it be possible, 84% of all patients admit that they are
willing to self-administer their medication leading to increased patient independence,
satisfaction, and increased knowledge about their drugs (Vanwesemael et al., 2018). There are
several skills required by patients for self-administration of emicizumab-kxwh such as bleed
recognition, record keeping of their regimen and self-infusion skills (Srivastava et al., 2020).
Self-administration of emicizumab-kxwh also eliminates the need for central venous access
devices (CVADs) in paediatric patients which can often become infected, and venous access
in adults which can sometimes be difficult (Srivastava et al., 2020). For paediatric patients and
patients who require care assistants, self-administration may not be possible. A study conducted
by Hoffmann-La Roche, (2021) showed that 100% of care givers preferred emicizumab-kxwh
administration over other haemophilia A prophylactic treatments as it allowed a lower
treatment frequency and had less of an impact on daily activities.
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The main benefit of emicizumab-kxwh can be observed by the report from HAVEN 3 that
demonstrates that the ABR decreased by 68% when a haemophilia A patient moved from FVIII
concentrates prophylaxis to emicizumab-kxwh prophylaxis (Mahlangu et al., 2018). Even
though emicizumab-kxwh is not readily available worldwide, it is thought to be a cost-effective
treatment as it decreases hospital visits, morbidity, and mortality for the patients (Srivastava et
al., 2020). The decreased ABR in conjunction with self-administration and less hospitalisations
and deaths provides clear evidence for patients to move to emicizumab-kxwh therapy when
possible. Although thus far, congenital haemophilia A has been the focus of studies,
Emicizumab-kxwh has also been reported to be an effective agent to treat acquired haemophilia
A (Knoebl et al., 2021).

DISADVANTAGES OF EMICIZUMAB-KXWH
While emicizumab-kxwh offers several advantages as a haemophilia A prophylaxis over other
therapies, there are also some concerns associated with the drug that should not be overlooked.
Young et al., (2019), reported that nasopharyngitis and site injection reactions were observed
in 37.5% and 30.7%, respectively, of paediatric participants in the HAVEN 2 study. However,
these were all considered non-serious events and did not require treatment. Other adverse
events that have been noted less commonly in patients using emicizumab-kxwh are headaches,
arthralgia, upper respiratory tract infections and pain in extremities (Pipe et al., 2019).
One of the more serious complications that have been observed in patients using
emicizumabkxwh is thrombotic microangiopathy (TMA). This complication has been observed
in two patients using 1.5 mg/kg per week emicizumab-kxwh who experienced a breakthrough
bleed and were treated with aPCC (Oldenburg et al., 2017). Therefore, it is recommended that
patients who experience breakthrough bleeding are treated with episodic recombinant FVII
(rFVII) or other bypassing agents. However, should aPCC be the only bypassing agent
available, the lowest dose expected to achieve haemostasis should be administered (Young et
al., 2019).
A dilemma currently faced by many clinicians prescribing patients with emicizumab-kxwh is
the efficacy of the drug over time and the development of ADAs with neutralising potential.
ADAs have been reported in clinical trials, with two participant showing neutralising potential
causing emicizumab-kxwh to have a loss of efficacy (Young et al., 2019). This may be a cause
for concern as more patients begin to use the drug and long-term data is unavailable.
Additionally, should patients develop ADAs after using emicizumab-kxwh for some time, a
change of therapy may be required. As 20% of patients develop inhibitors to FVIII concentrates
(Walsh et al., 2015) and there are concerns that older / adult patients using FVIII concentrates
for the first time may have a large immune response to the drug there are suggestions that age
should be aforethought when considering a switch of therapies at a later age (Krishna and
Nadler, 2016). Perhaps this could be overcome by administering low doses of FVIII
concentrates infrequently in conjunction with emicizumab-kxwh.
While emicizumab-kxwh offers many advantages to haemophilia A patients, it is not available
in many parts of the world and several countries still rely on fresh frozen plasma (FFP).
Developed countries have moved away from the use of FFP due to the risks associated with
bacterial and viral pathogens being present (Srivastava et al., 2020). Therefore, treatment
options for patients often rely on the cost and availability of therapies.
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CONCLUSIONS
Despite the prospect that gene therapy could have revolutionised haemophilia A therapy,
unexpectedly emicizumab-kxwh, a bi-specific antibody, has done just that. This therapy offers
a convenient and highly effective alternative to FVIII concentrates that have been the standard
approach to therapy for several years. Furthermore, emicizumab-kxwh may be the only
effective therapy available for bleeding control for some haemophilia A patients with high titres
of FVIII inhibitors. However, this is not to suggest that gene therapy will not offer a permanent
treatment option in the future.
Suggestions have been made that emicizumab-kxwh should be administered as it demonstrates
superiority to FVIII concentrates and offers several advantages to haemophilia A patients (Le
Quellec and Negrier, 2018; Oldenburg et al., 2017). It is now the recommended treatment by
the World Haemophilia Federation for patients who possess a FVIII inhibitor and are at risk of
haemorrhage (Srivastava et al., 2020). However, as there is an increase in the administration of
this drug, there may need to be a standardised approach to laboratory testing considered.
The future regarding therapies for haemophilia A is optimistic since the approval of
emicizumab-kxwh for routine use. Current and future trials include the investigation of
emicizumab-kxwh during minor surgical procedures and the investigation of the efficacy of
emicizumab-kxwh in moderate and severe haemophilia A patients playing sports. This may
provide evidence that haemophilia A patients, even those with the severe form, could be
empowered to live a relatively normal life without too much concern for bleeding events.
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